Important Safety Information

Contraindication: Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig® in post marketing experience. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. If a serious or severe reaction occurs, discontinue Aimovig® and initiate appropriate therapy.

Constipation with Serious Complications: Constipation with serious complications has been reported following the use of Aimovig® in the postmarketing setting. There were cases that required hospitalization, including cases where surgery was necessary. The onset of constipation was reported after the first dose in a majority of these cases, but patients also reported later on in treatment. Aimovig® was discontinued in most reported cases. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies.

Monitor patients treated with Aimovig® for severe constipation and manage as clinically appropriate. Concurrent use of medications associated with decreased gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of Aimovig® in the postmarketing setting. Many of the patients had pre-existing hypertension or risk factors for hypertension. There were cases requiring pharmacological treatment and, in some cases, hospitalization. Hypertension may occur at any time during treatment but was most frequently reported within seven days of dose administration. In the majority of the cases, the onset or worsening of hypertension was reported after the first dose. Aimovig® was discontinued in many of the reported cases.

Monitor patients treated with Aimovig® for new-onset hypertension, or worsening of pre-existing hypertension, and consider whether discontinuation of Aimovig® is warranted if evaluation fails to establish an alternative etiology.

Adverse Reactions: The most common adverse reactions in clinical studies (≥ 3% of Aimovig®-treated patients and more often than placebo) were injection site reactions and constipation.

Please see Aimovig® full Prescribing Information.


Indication

Aimovig® is indicated for the preventive treatment of migraine in adults.

In person or via telemedicine, the resources to help start your patients on Aimovig® are right here

For your convenience, we have gathered all the resources you may find helpful to start and support patient treatment with Aimovig®.

1. Starting patients on Aimovig®

Helping your patients get the resources to start Aimovig®.

Download all starter materials

Dosing Reference Guides

Aimovig® is available in once-monthly doses of 70 mg and 140 mg.1 You can download the one-page reference guides below.

The 70 mg and 140 mg Instructions for Use and the Aimovig® Injection Video may also be helpful tools for your patients.

Download guides

Aimovig Ally™ Access Card

Your commercially insured eligible patients can get Aimovig® free for up to 12 dosesx If the patient’s health plan does not cover Aimovig® or requires a prior authorization, the patient can qualify for the Bridge to Commercial Coverage Offer and receive Aimovig® free for up to 12 doses, while pursuing approval from their health plan. No purchase necessary. See full Terms and Conditions below. or for a $5 monthly copay.x If Aimovig® is approved by the patient’s health plan, a patient pays a $5 copay per month, up to a maximum benefit of $3500 annually. This applies to patient out-of-pocket costs, including deductible, co-insurance, and copayments for Aimovig®. Patient is responsible for costs above the annual maximum. See full Terms and Conditions below.

Terms and Conditions apply. Click here for details.

Download

Onboarding Brochure

A single resource to help patients new to Aimovig® start and stay on treatment as prescribed.

Download
2. Tools to help get your patients covered

More than 90% of prescriptions are approved by the patient's insurer.2 Aimovig® offers different options based on insurance coverage.

  • With the Aimovig Ally™ Access Card, commercially insured eligible patients can get Aimovig® free for up to 12 dosesx If the patient’s health plan does not cover Aimovig® or requires a prior authorization, the patient can qualify for the Bridge to Commercial Coverage Offer and receive Aimovig® free for up to 12 doses, while pursuing approval from their health plan. No purchase necessary. See full Terms and Conditions below. or for a
    $5 copayx If Aimovig® is approved by the patient’s health plan, a patient pays a $5 copay per month, up to a maximum benefit of $3500 annually. This applies to patient out-of-pocket costs, including deductible, co-insurance, and copayments for Aimovig®. Patient is responsible for costs above the annual maximum. See full Terms and Conditions below. per month.
    Terms and Conditions apply. Click here for details.
  • If the patient's health plan does not cover Aimovig® or requires prior authorization (PA), the patient can qualify for the Bridge to Commercial Coverage Offer
  • Those who are uninsured or have insurance that excludes Aimovig® may be eligible under the Amgen Safety Net Foundation. Learn more here

Here are a few resources and forms that may be helpful for gaining access to Aimovig®.

Download all coverage materials

Prior Authorization Support

Prior Authorizations can be filed through covermymeds.

Access our PA checklist below.

Go to PA checklist

Sample Letter of Appeal

Template to request a review of a denied claim for Aimovig®.

Download

Sample Letter of Medical Necessity

Template to file documentation that Aimovig® is medically necessary.

Download
3. Telemedicine resources

The use of telemedicine and remote care services to treat patients has been increasing over time, and in some situations, may be essential. Here are a few telemedicine and remote care resources that you may find valuable.

CMS guidance on CPT and HCPCS codes:

https://www.cms.gov/newsroom/fact-sheets/medicare-telemedicine-health-care-provider-fact-sheet

AMA guidance on telemedicine coding:

https://www.ama-assn.org/practice-management/digital/ama-quick-guide-telemedicine-practice

AAN guidance on telemedicine and remote care:

https://www.aan.com/practice/telemedicine/

Disclaimer: These links are being provided as a convenience and for informational purposes only; they do not constitute an endorsement or an approval by Amgen and Novartis of any of the products, services, or opinions of the organization or individual. Amgen and Novartis bear no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.

Have more questions?

Simply call 833-AIMOVIG (833-246-6844), Monday–Friday, 8:00 am–9:00 pm ET.
You’ll receive live support for your questions from knowledgeable representatives.

Terms and Conditions for Bridge to Commercial Coverage Offer (“Bridge Offer”): Aimovig® free for up to 12 doses over 24 months (whichever occurs first) from the first prescription filled under the Bridge Offer. Available if patient has a prescription, is commercially insured, and 18 years or older. This offer is not valid if patient is uninsured or receiving prescription reimbursement under any federal-, state-, or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, the Retiree Drug Subsidy Program, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD), or TRICARE or where prohibited by law. Cash Discount Cards and other noninsurance plans are not valid as primary under this offer. If at any time patient begins receiving coverage under any such federal-, state-, or government funded healthcare program, patient will no longer be able to use this offer and patient must call 833-AIMOVIG to stop participation. By participating in this offer, patient acknowledges intent to pursue insurance coverage for Aimovig® with their healthcare provider. Ongoing eligibility requires that patient has a prior authorization or medical exception denied within 90 days of first use of offer. Once insurance approval is obtained, patient is no longer eligible for this offer. No purchase necessary. This is not health insurance. Participation is not a guarantee of insurance coverage. This offer is not renewable. Valid in the United States, Puerto Rico, and the US territories. Other restrictions may apply. This offer is subject to change or discontinuation without notice.

Terms and Conditions for Copay Offer: Pay a $5 copay per month, up to a maximum benefit of $3500 annually. Available if patient has a prescription, is commercially insured, and 18 years or older. This offer is not valid if patient is uninsured or receiving prescription reimbursement under any federal-, state-, or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, the Retiree Drug Subsidy Program, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD), or TRICARE or where prohibited by law. Cash Discount Cards and other noninsurance plans are not valid as primary under this offer. If at any time patient begins receiving coverage under any such federal-, state-, or government-funded healthcare program, patient will no longer be able to use this offer and patient must call 833-AIMOVIG to stop participation. Patient may not seek reimbursement for value received from this offer from any third-party payers, including flexible spending accounts or healthcare savings accounts. This is not health insurance. Participation is not a guarantee of insurance coverage. Valid in the United States, Puerto Rico, and the US territories. Other restrictions may apply. This offer is subject to change or discontinuation without notice. If you become aware that your health plan or pharmacy benefit manager does not allow the use of manufacturer copay support as part of your health plan design, you agree to comply with your obligations, if any, to disclose your use of the card to your insurer. This offer is ongoing and in order to remain eligible, patient must re-enroll every 12 months by visiting www.aimovigaccesscard.com/ or by calling 833-AIMOVIG (833-246-6844).

Indication

Aimovig® is indicated for the preventive treatment of migraine in adults.

Important Safety Information

Contraindication: Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig® in post marketing experience. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. If a serious or severe reaction occurs, discontinue Aimovig® and initiate appropriate therapy.

Constipation with Serious Complications: Constipation with serious complications has been reported following the use of Aimovig® in the postmarketing setting. There were cases that required hospitalization, including cases where surgery was necessary. The onset of constipation was reported after the first dose in a majority of these cases, but patients also reported later on in treatment. Aimovig® was discontinued in most reported cases. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies.

Monitor patients treated with Aimovig® for severe constipation and manage as clinically appropriate. Concurrent use of medications associated with decreased gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of Aimovig® in the postmarketing setting. Many of the patients had pre-existing hypertension or risk factors for hypertension. There were cases requiring pharmacological treatment and, in some cases, hospitalization. Hypertension may occur at any time during treatment but was most frequently reported within seven days of dose administration. In the majority of the cases, the onset or worsening of hypertension was reported after the first dose. Aimovig® was discontinued in many of the reported cases.

Monitor patients treated with Aimovig® for new-onset hypertension, or worsening of pre-existing hypertension, and consider whether discontinuation of Aimovig® is warranted if evaluation fails to establish an alternative etiology.

Adverse Reactions: The most common adverse reactions in clinical studies (≥ 3% of Aimovig®-treated patients and more often than placebo) were injection site reactions and constipation.

Please see Aimovig® full Prescribing Information.

References: 1. Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123-2132. 2. Aimovig® (erenumab-aooe) prescribing information, Amgen. 3. Goadsby PJ, Reuter U, Hallström Y, et al. Sustained efficacy over 1 year of treatment with erenumab: results from the extension phase of the STRIVE study in episodic migraine. Poster presented at: 12th European Headache Federation Congress (EHF); September 28–30, 2018; Florence, Italy. 4. Ashina M, Goadsby PJ, Reuter U, et al. Sustained efficacy and long-term safety of erenumab in patients with episodic migraine: 4+-year results of a 5-year, open-label treatment period. Oral presentation at: American Headache Society, 61st Annual Scientific Meeting; July 11-14, 2019; Philadelphia, PA. 5. Sun H, Dodick DW, Silberstein S, et al. Appendix for: Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomized, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(4):382-390. 6. Ashina M, Tepper SJ, Brandes JL, et al. Efficacy and safety of erenumab (AMG 334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2018;38(10):1611-1621. 7. Ashina M, Goadsby PJ, Reuter U, et al. Long-term safety and tolerability of erenumab: three-plus year results from an ongoing open-label extension study in episodic migraine. Oral presentation at: American Headache Society, 60th Annual Scientific Meeting; June 28–July 1, 2018; San Francisco, CA. 8. Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425-434. 9. Tepper SJ, Ashina M, Reuter U, et al. Assessment of the long-term safety and efficacy of erenumab during open-label treatment in subjects with chronic migraine. Poster presented at: American Headache Society, 60th Annual Scientific Meeting; June 28–July 1, 2018; San Francisco, CA. 10. Data on file, Amgen Inc. AMG 334 Clinical Study Report: 20130255 Final Analysis. February 16, 2018. 11. Brossner G, Reuter U, Bonner J, et al. Achievement of ≥ 75% and 100% response in patients treated with erenumab: 24-week results from the STRIVE study. Poster presented at: 18th Congress of the International Headache Society; September 7-10, 2017; Vancouver, Canada. 12. Data on file, Amgen Inc. AMG 334 Abbreviated Clinical Study Report: 20120178. January 28, 2016. 13. Data on file, Amgen Inc. AMG 334 Abbreviated Clinical Study Report: 20120296. July 16, 2018. 14. Data on file, Amgen Inc. AMG 334 Clinical Study Report: 20130255 Final Analysis. February 16, 2018.